Valeur202020212022202320242025TTMFrais de vente, généraux et administratifs5.73 B5.37 B5.41 B6.18 B7.1 B7.05 B6.96 BRecherche et développement4.21 B6.32 B4.43 B4.78 B5.96 B7.27 B7.5 BRésultat d'exploitation9.14 B7.64 B9.57 B7.9 B7.26 B9.08 B10.57 BTotal des produits hors exploitation256 M259 M-814 M2.83 B506 M2.65 B1.21 BCharges d'intérêts, nettes des intérêts capitalisés1.26 B1.2 B1.41 B2.88 B3.15 B2.75 B2.69 BRésultat hors exploitation, hors charges d'intérêts256 M259 M-814 M2.83 B506 M-104 M-1.48 BRevenus/dépenses exceptionnels———————Résultat avant impôts8.13 B6.7 B6.46 B7.86 B4.61 B8.98 B16.55 BPart des actionnaires dans le résultat——-891 M-11 M10 M——Impôts869 M808 M794 M1.14 B519 M1.26 B1.29 BIntérêts ne donnant pas le contrôle / intérêts minoritaires———————Autres produits/charges après impôts195 M229 M176 M-563 M8 M-149 M-132 MRésultat net avant activités abandonnées7.26 B5.89 B6.55 B6.72 B4.09 B7.71 B7.8 BActivités abandonnées———————Résultat net7.26 B5.89 B6.55 B6.72 B4.09 B7.71 B7.8 BAjustement de dilution———————Dividendes privilégiés———————Résultat net dilué revenant aux actionnaires ordinaires7.26 B5.89 B6.55 B6.72 B4.09 B7.71 B7.8 BBénéfice par action de base (BPA de base)12.410.3412.1812.567.6214.3314.48Bénéfice par action dilué (BPA dilué)12.3110.2812.1112.497.5614.2314.37Nombre moyen d'actions de base en circulation586 M570 M538 M535 M537 M538 M—Nombre d'actions en circulation après dilution590 M573 M541 M538 M541 M542 M—EBITDA12.74 B11.04 B12.98 B11.97 B12.85 B14.25 B15.46 BEBIT9.14 B7.64 B9.57 B7.9 B7.26 B9.08 B10.57 BCoût des ventes6.16 B6.45 B6.41 B8.45 B12.86 B12.04 B11.81 BAutres coûts des ventes———————Amortissements (flux de trésorerie)3.6 B3.4 B3.42 B4.07 B5.59 B5.17 B4.9 B
Amgen Inc. - Common Stock
Amgen Inc. is an American multinational biopharmaceutical company headquartered in Thousand Oaks, California. The company is ranked 18th on the list of largest biomedical companies by revenue. The name "AMGen" is a portmanteau of the company's original name, Applied Molecular Genetics.
The company's major products are Prolia and XGEVA for treatment of osteoporosis and bone diseases, Enbrel for treatment of autoimmune diseases, Repatha for treatment of hyperlipidemia, Otezla for treatment of psoriasis and psoriatic arthritis, Tepezza to treat Graves' ophthalmopathy, Evenity to treat osteoporosis, Kyprolis to treat cancer, Nplate to regulate platelet production, and Aranesp to stimulate erythropoiesis.
Amgen has 17 clinical programs underway in Phase III, eight in Phase II, and 19 in Phase I. Its pipeline includes MariTide, an anti-obesity medication administered once per month by injection.
The company receives approximately 80% of its revenues from sales to the three large U.S. drug wholesalers: McKesson Corporation, Cencora, and Cardinal Health.
The company is ranked 134th on the Fortune 500 and 202nd on the Forbes Global 2000.